Systemic therapies in hepatocellular carcinoma: Existing and emerging biomarkers for treatment response

Hepatocellular carcinoma (HCC) is the fifth most common malignancy and the third most common cause of cancer-related death worldwide. Due to asymptomatic patients in the early stage, most patients are diagnosed at an advanced stage and lose the opportunity for radical resection. In addition, for pat...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Penghui, Wan, Haifeng, Wan, Juan, Jiang, Hanyu, Yang, Yu, Xie, Kunlin, Wu, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9723250/
https://www.ncbi.nlm.nih.gov/pubmed/36483039
http://dx.doi.org/10.3389/fonc.2022.1015527

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9723250/
https://www.ncbi.nlm.nih.gov/pubmed/36483039
http://dx.doi.org/10.3389/fonc.2022.1015527

Ejemplares similares